Prospective, Single Arm, Open-label, Multicenter, International Study to Assess the Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome During a 12-week Treatment Period Followed by an Extension Period of 24 Weeks

Trial Profile

Prospective, Single Arm, Open-label, Multicenter, International Study to Assess the Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome During a 12-week Treatment Period Followed by an Extension Period of 24 Weeks

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Metyrapone (Primary)
  • Indications Cushing syndrome
  • Focus Therapeutic Use
  • Acronyms PROMPT
  • Sponsors HRA Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Feb 2017 Planned End Date changed from 1 Sep 2018 to 1 Nov 2018.
    • 14 Feb 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top